摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-FLUORO-4-BIPHENYLMAGNESIUM BROMIDE | 76699-46-2

中文名称
——
中文别名
——
英文名称
2-FLUORO-4-BIPHENYLMAGNESIUM BROMIDE
英文别名
(2-fluoro-1,1’-biphenyl-4yl)magnesium bromide;2-fluoro[1,1'-biphenyl]-4-magnesium bromide;(3-fluoro-4-phenyl)phenyl magnesium bromide;2-fluoro-4-biphenylylmagnesium bromide
2-FLUORO-4-BIPHENYLMAGNESIUM BROMIDE化学式
CAS
76699-46-2
化学式
C12H8BrFMg
mdl
——
分子量
275.403
InChiKey
NQSUQAQPOPPGIN-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.13
  • 重原子数:
    15.0
  • 可旋转键数:
    2.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    0.0
  • 氢给体数:
    0.0
  • 氢受体数:
    0.0

安全信息

  • 海关编码:
    2931900090

SDS

SDS:1a262d288741e2fb8657822e56468d6c
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Enantioselective Synthesis of α-Methyl Carboxylic Acids from Readily Available Starting Materials via Chemoenzymatic Dynamic Kinetic Resolution
    作者:Lisa K. Thalén、Anna Sumic、Krisztián Bogár、Jakob Norinder、Andreas K. Å. Persson、Jan-E. Bäckvall
    DOI:10.1021/jo1011653
    日期:2010.10.15
    enantioselective method for the synthesis of α-methyl carboxylic acids starting from trans-cinnamaldehyde, a readily available and inexpensive compound, has been developed. Allylic alcohol 1 was obtained via a standard Grignard addition to trans-cinnamaldehyde. Dynamic kinetic resolution was applied to allylic alcohol 1 utilizing a ruthenium catalyst and either an (R)-selective lipase or an (S)-selective protease
    已经开发了从反式肉桂醛(一种容易获得且便宜的化合物)开始合成α-甲基羧酸的对映选择性方法。通过反式肉桂醛的标准格氏试剂获得烯丙醇1。动态动力学拆分应用于烯丙基醇1利用催化剂和任一种([R ) -选择性脂肪酶或(小号选择性蛋白酶以高产率和高ee提供相应的烯丙基酯。然后应用催化的烯丙基取代,以提供相应的具有立体化学反转的烯烃。随后的C-C双键裂解可提供高ee值和高达76%的总收率的药学上重要的α-甲基取代的羧酸
  • 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
    申请人:SFC CO., LTD. 에스에프씨 주식회사(120060087061) Corp. No ▼ 135511-0105889BRN ▼134-81-54429
    公开号:KR102118013B1
    公开(公告)日:2020-06-05
    본 발명은 하기 [화학식 A]로 표시되는 유기 발광 화합물 및 이를 포함하는 유기 발광 소자에 관한 것으로, 치환기 A1 내지 A4, R1 내지 R15, X1, X2, Y, n, q 및 L은 발명의 상세한 설명에 정의된 바와 동일하다. [화학식 A]
    本发明涉及如下[化学式A]所示的有机发光化合物以及包含该化合物的有机发光器件,其中取代基A1至A4,R1至R15,X1,X2,Y,n,q及L与发明详细描述中定义的相同。[化学式A]
  • Synthesis of a TNF inhibitor, flurbiprofen and an <i>i</i>-Pr analogue in enantioenriched forms by copper-catalyzed propargylic substitution with Grignard reagents
    作者:Yuji Takashima、Yukari Isogawa、Atsuki Tsuboi、Narihito Ogawa、Yuichi Kobayashi
    DOI:10.1039/d1ob01944a
    日期:——
    Furthermore, the substitution of phosphates derived from TMSCCCH(OH)CH3 and TMSCCCH(OH)-i-Pr with 3-F-4-PhC6H3MgBr gave the corresponding substitution products, which were transformed to flurbiprofen and its i-Pr analogue, respectively. The copper-catalyzed substitutions in these syntheses proceeded in a regio- and stereoselective manner.
    由 TMSC CCH(OH)CH 2 CH 2 OTBDPS 衍生的磷酸二乙酯与 3- c -C 5 H 9 -4-MeOC 6 H 3 MgBr在催化下发生取代反应,然后进行多次转化,得到肿瘤坏死因子抑制剂具有Ph-乙炔部分。该抑制剂也由磷酸苯乙炔PhC CCH(OP(O)(OEt) 2 )CH 2 CH 2 OTBDPS合成。此外,衍生自 TMSC CCH(OH)CH 3和 TMSC CCH(OH)- i -Pr 的磷酸盐被 3-F-4-PhC 6 H取代3 MgBr 得到相应的替代产物,分别转化为氟比洛芬及其i- Pr 类似物。这些合成中的催化取代以区域选择性和立体选择性方式进行。
  • Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
    申请人:Suntory Limited
    公开号:US06455549B1
    公开(公告)日:2002-09-24
    A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or —NHCO(CH2)n— where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.
    一种制药组合物,特别是用于缓解或治疗缺血性疾病和因癫痫、癫痫和偏头痛引起的症状的制药组合物,以及Ca2+过载抑制剂,含有具有以下式(I)的芳基哌啶醇或芳基哌啶生物:其中,R是H,可选择地取代的苯基,可选择地取代的苯氧基,或可选择地取代的苯甲酰基,A是连接键,环烷烃基,或可选择地取代的烯烃基,B是可选择地取代的烷基,其中取代基为OH或烷氧基,或-NHCO(CH2)n—,其中n为1至5的整数,E是连接键,O,或亚甲基,X是OH或H,条件是当E为O或亚甲基时,X不是H,Y和Z分别是H,卤素,烷氧基,或可选择地取代的烷基,其取代基为卤素。
  • Disubstituted ethanes and their use in liquid crystal materials and devices
    申请人:Secretary of State for Defence in Her Britannic Majesty's Gov. of the United Kingdom of Great Britain and Northern Ireland
    公开号:EP0117631A1
    公开(公告)日:1984-09-05
    A fluorinated compound having a formula: wherein: R, is hydrogen or alkyl having up to 12 carbon atoms; R2 is selected from hydrogen, alkyl having up to 12 carbon atoms, alkoxy having up to 12 carbon atoms, wherein R3 is hydrogen or alkyl having up to 12 carbon atoms, and wherein R4 is hydrogen, alkyl having up to 12 carbon atoms or alkoxy having up to 12 carbon atoms; represents a cyclohexane ring which is in the trans configuration if 1,4-disubstituted; represents a benzene ring; each of X, Y and Zindependently represents hydrogen or fluorine in one or more of the lateral benzene ring positions, provided that at least one of X, Y and Z is present representing fluorine; n = 0 or 1 provided that when is and R, is alkyl; with the proviso that in Formula l when n is 1 and where R is n-alkyl and R2 is n-alkyl or n-alkoxy the total number of carbon number of carbon plus oxygen atoms in the two groups R1 and R2 is less than 10.
    一种含化合物,其式如下 其中 R 是氢或最多有 12 个碳原子的烷基; R2选自氢、最多具有12个碳原子的烷基、最多具有12个碳原子的烷氧基、 其中 R3 是氢或最多具有 12 个碳原子的烷基,R4 是氢、最多具有 12 个碳原子的烷基或最多具有 12 个碳原子的烷氧基; 代表环己烷环,如为 1,4-二取代环,则为反式构型; 代表一个苯环; X、Y 和 Z 各自独立地代表氢或位于一个或多个苯环侧位的,条件是 X、Y 和 Z 中至少有一个代表; n = 0 或 1,条件是当 是 且 R 为烷基;但在式 l 中,当 n 为 1 且 其中 R 为正烷基,R2 为正烷基或正烷氧基时,R1 和 R2 两个基团中碳原子加氧原子的总数小于 10。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫